A closer look at “FTC Seeks Contempt Ruling Against Martin Shkreli Over Pharma Stock Holdings”, exactly as the source publishes it. The Federal Trade Commission has asked a federal court to hold Martin Shkreli in contempt, alleging he violated a court order that banned him from working in the pharmaceutical industry. The order stems from a 2022 ruling that found Shkreli liable for anticompetitive conduct related to Daraprim pricing while he was CEO of Turing Pharmaceuticals. The FTC now demands that Shkreli divest his pharmaceutical stocks, arguing that his continued ownership constitutes a violation of the ban.
Shkreli, who gained notoriety for raising the price of the life-saving drug Daraprim by over 5,000% in 2015, was previously sentenced to seven years in prison for securities fraud. The FTC's move signals an aggressive enforcement stance against individuals who flout antitrust remedies, reinforcing that court orders carry real consequences. This listing links straight to the original page, where the content is available in full.